Bolt Biotherapeutics (BOLT) vs NeuroSense Therapeutics (NRSN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Bolt Biotherapeutics is the larger company by market cap ($7.6 million vs $7.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BOLT | NRSN |
|---|---|---|
| Share price | $3.95 | $3.80 |
| Market cap | $7.61M | $7.22M |
| 1-day change | +8.82% | +1.71% |
| EPS (TTM) | $-16.51 | $-47.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.20 | $26.64 |
| 52-week low | $3.10 | $3.56 |
| Distance from 52-week high | -45.14% | -85.72% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +634.18% | +2458.56% |
| Average volume | 26.26K | 21.29K |
| Shares outstanding | 1.93M | 1.90M |
| Employees | 23 | 17 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bolt Biotherapeutics
BOLT stock →Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
BOLT vs NRSN FAQ
Which is bigger, Bolt Biotherapeutics or NeuroSense Therapeutics?
Bolt Biotherapeutics (BOLT) is larger, with a market capitalization of $7.61M compared with $7.22M for NeuroSense Therapeutics (NRSN).
Are Bolt Biotherapeutics and NeuroSense Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.